| abstract |
The present invention relates to the use of an isolated human antibody or an antigen-binding portion thereof which dissociates from human TNFα in the manufacture of a medicament for the treatment of a disorder in which TNF α activity is detrimental wherein the antibody is administered in combination with at least one additional agent to a subject, so that human TNF α activity is inhibited. |